Upload
others
View
5
Download
0
Embed Size (px)
Citation preview
Clinical Pharmacogenomics David A Flockhart MD, PhD
Chief, Division of Clinical Pharmacology
Professor of Medicine, Genetics and Pharmacology
Indiana University School of Medicine
December 6, 2012
2
Outline
Pharmacogenomics and rationale for the use of pharmacogenomics in the
clinic
Basic principals for the value of pharmacogenomics
The unmet disease burden and the opportunity.
Pharmacogenomic opportunities and their clinical utility in cancer,
cardiovascular disease and psychiatry
Avoiding pitfalls and optimizing clinician uptake
3
Outline Pharmacogenomics and rationale for the use of pharmacogenomics in the
clinic
Basic principals for the value of pharmacogenomics
The unmet disease burden and the opportunity.
Pharmacogenomic opportunities and their clinical utility in cancer,
cardiovascular disease and psychiatry
Avoiding pitfalls and optimizing clinician uptake
4
The Genetic Evolution
(Arrow pointing down to the left)
One Gene, One SNP
One Gene, Multiple Variants
Multiple Genes, Multiple Variants
Pathways, Multiple Variants
All Variants in the Genome
5
SNP Variability in The Human Genome
December 2011
2.85 billion base pairs
~22,000 genes
1.7% of the genome codes for protein
3.3% of the genome is as conserved as the 1.7% that codes for
protein
On average 1 SNP/1.2kb
10 - 15 million SNPs that occur at > 1% frequency
~450,000 SNPs in Multiply Conserved Regions
Copy number variations exist in 5-7.5% of the germline genome
Most tumor DNA sequence is identical to that of the host
4-5% of the genome is in areas with high copy number variation
6
Genome Wide Association as a Tool for Personalized
Medicine: Effect Sizes are generally low
Graph of diseases/traits studied
Fletcher RL, Flockhart DA, 2011
7
Pharmacogenomic Genome-Wide Association
Studies
Warfarin : CYP2C9
Clopidogrel: CYP2C19
Simvastatin: SLC101
Exemestane and Anastrozole:
Tamoxifen :
8
Drugs and Their Available Pharmacogenetic Tests
(As of September, 2011. most are monogenic tests)
Abacavir HLA *B5701
Alcoho l ADH and ALDH
Interferon α I l28B
Clopidogrel CYP2C19
Venlafaxine CYP2D6
Codeine and hydrocodone CYP2D6
Tamoxifen CYP2D6
Methadone CYP2B6
Vincristine CYP3A5
Tacrolimus CYP3A5
Cyclophosphamide CYP2B6
Metformin OATP3
Imatinib BCR-ABL
5-Fluorouracil DPYD-TYMS
Clozapine 2 SNPs in HLA-DQB1
Irinotecan UGT1A1
Azathioprine and Mercaptopurine TPMT
Warfarin CYP2C9 and VKCoR
Carbamazepine HLA-B* 1502
QT-prolonging Drugs Familion™
Adapted from Flockhart DA et al. Clin Pharmacol Ther. 2009
Jul;86(1):109-13
9
Many are Available But Which Tests Are
Valuable?
Analytical Validity
Laboratory Integrity
Clinical Validity
Accurate biomarker prediction
Clinical Utility
Would it change what you do?
i.e. change a drug or dose
10
Principal Factors that Influence the Clinical Value of
Any Pharmacogenomic Test
- Is there large variance is treatment outcomes?
- Are alternative therapies available?
- What’s the current predictive value?
Graph of Clinical value of a pharmacogenetic test and current
clinical ability to predict response
11
Principles for Valuable Pharmacogenetic Tests
1. Large variance in treatment outcomes
2. Alternative therapies are available
3. Current predictive ability is low
4. Significant clinical consequences
5. Economically viable
Graph of clinical value of pharmagogenetic test
12
Determining Whether Variability is Present:
The Simple Polymorphic Distribution
Chart showing population frequency and activity (Phenotype)
and antimode.
13
The Value of Normit Distribution Plots: (an example is shown)
Population Distribution of CYP2C19 phenotype (an example is
shown)
Flockhart et al: Clin Pharmacol Ther
1995;57:662-669
14
Skewed Distribution
The Mean is Not the Same as the Mode
A chart is shown indicating the population frequency and
activity (Phenotype).
15
Example 1 of a Skewed Distribution: Heterogeneity in
response to Inhaled Corticosteroids
A bar chart is shown indicating the Patients, %, and the % change
in FEV, from baseline for the adult study, CAMP and ACRN.
Weiss ST et al. Hum Molec Genetics 2004; 13:1353-11359
16
The Problem with Mean Response Data: Heterogeneity in
Response to Medicines in Clinical Trials
Shows the Frequency of various responses in the RCT treated
population
Evan B, Flockhart DA et al. (2010)
17
Consequences of Variable Treatment Response
-- The Unmet Medical Need
1. Cancer: Poor outcomes due to poor therapeutic efficacy and
the development of resistance
2. Cardiovascular Disease: High morbidity and mortality due to
persistent disease progression
3. Psychiatry: Inadequate treatment due to side effects, poor
compliance and lack of efficacy biomarkers
18
Consequences of Variable Treatment Response
-- The Unmet Medical Need
1. Cancer: Poor outcomes due to poor therapeutic efficacy and
the development of resistance
2. Cardiovascular Disease: High morbidity and mortality due to
persistent disease progression
3. Psychiatry: Inadequate treatment due to side effects, poor
compliance and lack of efficacy biomarkers
19
Pharmacogenomic Opportunities in Cancer
- Tamoxifen for Breast Cancer as an example
– Therapeutic ceiling in endocrine therapy
– Imperfect prediction of response
– Roadmap for prognostic tests
- ER, PR, HER2
- Precedent for multiplex arrays
– Highly organized tissue collection (tumor)
– Multiple retrospective trials to study
23
CYP2D6 Pharmacogenetics
Frequency histogram for Debrisoquine/4-Hydroxydebrisoquine
metabolic ratio in UMs, EMs, and PMs.
Dahl ML et al. J Pharmacol Exp Ther. 1995 Jul;274(1):516-20
26
UGT1A1 TA Repeat Genotype Altered
Irinotecan Neutropenia and Activity in Colon Cancer
Graphic illustration
McLeod H. et al, 2003
27
Irinotecan Pharmacogenomic Testing
- Analytical Validity OK
- Clinical Validity OK
- Clinical Utility unclear because the tests value is limited to
specific dosing regimes
- Not in widespread use
28
Thiopurine Methyl Transferase
- Cause of Highly Variable Toxicity : Granulocytopenia with
Mercaptopurines:Azathioprine and 6-Mercaptopurine Used
in:
- Acute Lymphocytic Leukemia in Children
- Inflammatory Bowel Disease in Adults
Homozygous mutants are 0.2% of Caucasian Populations
Heterozygotes are ~ 10%
Homozygous wild type is 90% – Metabolism of Azathioprine
– 6-Mercaptopurine
29
Variability in Thiopurine Methyl Transferase
Frequency histogram for TPMT activity in 298 unrelated adults.
From: Weinshilboum et al. JPET;222:174-81. 1982
32
Bevacizumab in Breast Cancer
Improvement in PFS/ORR did not translate into OS
benefit
Chart of progression-free survival.
ORR
(measurable disease)
49.2% vs. 25.2%
P<0.001
Miller et al. NEJM 357:2666;2007
33
Detailed chart from Miller et al. NEJM 357:2666;
2007 with the following sentence across it.
We need something better!
34
Pharmacogenetic Biomarkers VEGF -2578 AA & -
1154 AA genotypes in combination arm
outperformed control
Graph and illustration
35
Bevacizumab Pharmacogenomic Testing
- Analytical Validity OK
- Clinical Validity OK
- Clinical Utility Requires Validation
in Other Trials
Could a Pharmacogenomics Approach bring Avastin™ Back?
37
Consequences of Variable Treatment Response
-- The Unmet Medical Need
1. Cancer: Poor outcomes due to poor therapeutic efficacy and
the development of resistance
2. Cardiovascular Disease: High morbidity and mortality due to
persistent disease progression
3. Psychiatry: Inadequate treatment due to side effects, poor
compliance and lack of efficacy biomarkers
39
CYP2C19 generates the active metabolite of
Clopidogrel (Plavix™)
Simon et al. NEJM December 23rd, 2008
40
Comparison of prasugrel 60 mg and clopidogrel 600
mg loading dose exposure of active metabolite by
CYP2C19 genetic classification. Box represents
median, 25th, and 75th percentiles and whiskers
represent the most extreme values within 1.5 times
inter-quartile range of the box. AUC, area under the
concentration–time curve; EM, extensive
metabolizer; RM, reduced metabolizer.
Eur Heart J (2009) 30 (14): 1744-1752
41
Carriers of a CYP2C19 Genetic Variant
Experienced More Cardiovascular Events
Graph
Mega JL et al, NEJM, April, 2009
43
Pharmacogenomics Opportunities in
Cardiovascular Disease
• Warfarin for Deep Venous Thrombosis and Atrial Fibrillation
as an example
– A large population of patients treated
– Great variability in both efficacy and bleeding
outcomes
– Samples from many large prospective trials available
– International Normalized Ratio available as an existing
biomarker
44
VKORC1 Haplotype and CYP2C9 Genotype changed
Warfarin Dose Primary cohort: UW (N=185);
Replication cohort: Wash U (N=368).
All participants were Caucasian.
Rieder et al. N. Eng J. Med 2005;352: 2285-2293[
45
Pharmacogenomics Opportunities in
Cardiovascular Disease :Warfarin
• Analytical Validity OK
• Clinical Validity OK
• Clinical Utility
– limited because a viable alternative (INR) is available
in many, but not all practice settings.
• Not in widespread use.
47
Observed b1AR Haplotypes in Caucasians and
African American Women (WISE study)
Terra et al. Clin. Pharmacol. Ther. 71:70 (2002)
48
Of 10 theoretical diplotypes, only 4 were present in
the study population
Chart of haplotypes and diplotypes.
Ying-Hong Wang PhD, Indiana University School of Medicine
49
Diplotype predicted Beta-blocker effect: Single SNP
analysis Would Miss It.
Graph of change in diastolic blood pressure as a function of
diplotype.
Johnson et al. Clin Pharmacol & Ther. 2003,74:44-52.
50
Consequences of Variable Treatment Response
-- The Unmet Medical Need
1. Cancer: Poor outcomes due to poor therapeutic efficacy and
the development of resistance
2. Cardiovascular Disease: High morbidity and mortality due to
persistent disease progression
3. Psychiatry: Inadequate treatment due to side effects, poor
compliance and lack of efficacy biomarkers
52
Pharmacogenomic Opportunities in Psychiatry
• Venlafaxine for Depression as an example
– Blockbuster drug for a common disease
– Variability in efficacy and toxicity
– Prolonged time before efficacy is evident
– Need for biomarkers of treatment response
– Exclusive Metabolism by CYP2D6
– Large prospective trials with germline DNA available
53
Venlafaxine (VEN) Is Metabolized To
O-Demethylated-Venlafaxine (ODV) By CYP2D6
Br J Clin Pharmacol. 1996;41(2):149-156
54
CYP2D6 Genotype Associated with Venlafaxine
Efficacy
Lobello KW et al. J Clin Psychiatry 71:11, Nov. 2010
55
Promising pharmacogenomic opportunities exist in
cancer, cardiovascular disease and psychiatry.
How to implement?
56
Pharmacogenomic Pitfalls to Avoid
1. Inadequate testing of genetic variation
2. Inadequate analysis of known genetic variants
3. Poorly defined biomarker phenotypes
4. Inappropriate attempts to validate associations in
the wrong populations
5. Ineffective communication with the clinical
community
59
Iterative Statistical Analyses
From Discovery To Clinic Validation
Illustrations
Lang Li and David A. Flockhart, 2010
60
Outline
Pharmacogenomics and rationale for the use of
pharmacogenomics in the clinic
Basic principals for the value of pharmacogenomics
The unmet disease burden and the opportunity.
Pharmacogenomic opportunities in cancer,
cardiovascular disease and psychiatry
Avoiding pitfalls and optimizing clinician uptake
61
Optimizing Clinical Uptake
1. Simple and user-friendly informatic approaches
2. Education and raising awareness
3. Team approaches involving the whole
therapeutic alliance
4. Prospective trials of pharmacogenomic-guided
therapy versus standard-of-care
5. “Act local, think global”